EP2026666B1 - Compositions comestibles supprimant l'appetit contenant des glycosides steroïdiques - Google Patents

Compositions comestibles supprimant l'appetit contenant des glycosides steroïdiques Download PDF

Info

Publication number
EP2026666B1
EP2026666B1 EP07730088.7A EP07730088A EP2026666B1 EP 2026666 B1 EP2026666 B1 EP 2026666B1 EP 07730088 A EP07730088 A EP 07730088A EP 2026666 B1 EP2026666 B1 EP 2026666B1
Authority
EP
European Patent Office
Prior art keywords
product
steroidal glycoside
product according
steroidal
energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP07730088.7A
Other languages
German (de)
English (en)
Other versions
EP2026666A2 (fr
Inventor
Salomon Leendert Abrahamse
Kevin John Povey
Daryl David Rees
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council for Scientific and Industrial Research CSIR
Original Assignee
Council for Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council for Scientific and Industrial Research CSIR filed Critical Council for Scientific and Industrial Research CSIR
Priority to EP07730088.7A priority Critical patent/EP2026666B1/fr
Publication of EP2026666A2 publication Critical patent/EP2026666A2/fr
Application granted granted Critical
Publication of EP2026666B1 publication Critical patent/EP2026666B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates generally to appetite suppressant compositions. More particularly, it relates to unit serving appetite suppressant compositions comprising steroidal glycosides from plants of Hoodia genus.
  • Another proposed solution is to prescribe the individuals a specific diet, for example, a diet with a restricted caloric intake per day.
  • Meal replacement products have also been proposed as part of a healthy diet in order to control or reduce body weight.
  • US 5688547 discloses a nutritional meal replacement composition comprising dietary fiber, protein and a cellulose gum and gel.
  • Meal replacement products are generally products that are intended to be consumed as a single-serving food product, such as a bar, drink etc to replace one or two meals per day.
  • Commercial meal replacement products include, for instance, the Slim-Fast® brand (http://www.slim-fast.com). See also US 2005/0266137 (Eppler) and US 2005/018019 (Palmer ).
  • European Patent EP-A-994 655 discloses appetite suppressant compositions comprising an emulsion containing palm oil, oat oil and water.
  • Extracts from plants of the Hoodia genus which contain steroidal glycosides have also been shown to have an appetite suppressant activity. See US Patent 6,376,657 .
  • US 2005/0202103 discloses steroidal glycosides obtainable from Carolluma, another genus of plants in Asclepidaceae family.
  • US 7,008,648 discloses appetite suppression compositions containing steroidal glycosides obtainable from Stapelia and Orbea plants, additional plants within Asclepidoceae family.
  • US 2005/0276839 (Rifkin ) and US 2006/0083795 (Shatkina ) disclose appetite suppressant compositions containing Hoodia gordonii.
  • appetite suppressant unit serving products which are inherently nourishing providing at least a minimum of energy intake, yet also suppress appetite and maintain appetite suppression even at increased number of servings.
  • appetite suppressant products comprising Hoodia steroidal glycosides.
  • the invention is based at least in part on the discovery that the inventive product ensures that the appetite suppressant cannot be ingested (consumed) without the consumer getting a minimum daily level of energy intake, including essential minerals and preferably in the form of a healthy balance of proteins, fats and carbohydrates to total energy content; and furthermore that a relatively high number of products may be ingested while maintaining daily energy intake reduction and also preferably in the optimum ratio of steroidal glycosides to protein.
  • the inventive product provides healthy weight loss, yet avoids too rapid weight loss or insufficient energy intake by anorexics or extreme dieters.
  • the invention relates to a method of using such compositions for suppressing appetite and/or attaining daily energy reduction intake.
  • the average typical daily energy intake for an adult is around 10,000 kJ for women and around 13,000 kJ for man. It increases steadily with increasing BMI (body mass index) to up to 14,000 kJ for women and 18,000 kJ for men.
  • BMI body mass index
  • the method according to the invention may attain energy intake reductions of from 750 to 4500 kJ per day, more preferably from 1000 to 4500 kJ per day, most preferably from 2000 to 4000 kJ per day while maintaining adequate nutrition by balancing the longer term (typically 14 days or longer) effect of steroidal glycosides with the intake of essential good nutrition.
  • This reduction in daily energy intake is achieved even when a relatively high number of the unit servings are consumed per day, in addition to the regular daily energy intake.
  • the inventive products prevent consumer abuse of undernourishment which is a typical situation with a diet based on appetite suppressants in pills and/or very low calorie supplements.
  • the inventive products also promote consumer compliance by providing nutritious tasty products with sufficient nourishment.
  • the inventive method prevents consumers overeating or under-eating by correctly balancing desire to eat with nutrition provided.
  • any particular upper concentration can be associated with any particular lower concentration or amount.
  • the amounts of all ingredients besides the steroidal glycoside, including proteins, fats, carbohydrates, etc. are meant herein to be those that are delivered through ingredients other than the steroidal glycoside source (e.g., extract, plant, etc.).
  • Unit serving as used herein means an individual serving, designed for consumption at one time and, preferably individually packaged. It is sometimes also described herein as “single serving.”
  • a “drink” as used herein includes a dairy, fruit or vegetable based drink in either a sweet or savory base.
  • a "bar” as used herein includes snack or meal bars and also any small hand held and/or bite sized food product (e.g., cookies, muffins).
  • the inventive edible appetite suppressant compositions comprise a steroidal glycoside.
  • “Steroidal glycoside” as used herein means a steroid (four fused rings), further comprising at Least one side group substitution which is a glycoside (a molecule in which a sugar group is bonded through its anomeric carbon to another group via an O-glycosidic bond), preferably a deoxy or di-deoxy glycoside.
  • the steroidal glycoside is obtainable from Hoodia plants. This method is, disclosed in the US Patent 6,376,657 . Other methods of preparing steroidal glycosides are also acceptable.
  • the steroidal glycoside is delivered to the inventive compositions in the form of an extract from the Hoodia plants.
  • Suitable plants include but are not limited to Trichocaulon piliferum, Trichocaulon officinale , Hoodia currorii, Hoodia gordonii, Hoodia lugardii and mixtures thereof. More preferably, the plant extract is from Hoodia gordonii.
  • Suitable steroidal glycoside compounds include but are not limited to the general structural formula (1): wherein
  • Particularly preferred steroidal glycosides are analogs of Compound of Formula 1, extracted from the plants, including Compounds of Formula (2) through Formula (8), and mixtures thereof, obtainable from the Hoodia plants.
  • steroidal glycosides not specifically mentioned herein may be included in the inventive product. It will be understood that the invention also encompasses isomers, derivatives, salts, esters and analogs of the steroidal glycosides (preferably, biologically active) and mixtures thereof.
  • the product according to the invention comprises from 50 to 2000 milligrams ("mg"), preferably from 70 to 1500 mg, more preferably from 80 to 1200 mg, most preferably from 90 to 1100 mg, optimally from 100 to 1000 mg of a steroidal glycoside, in order to provide the optimum and consistent appetite suppressant response among the population from unit serving bars or drinks.
  • mg milligrams
  • the extract typically comprises at least 10%, by weight of the extract, of steroidal glycosides, preferably at least 20%, most preferably at least 60%, and optimally at least 70%.
  • US Patent 6,376,657 describes the preparation of a suitable extract comprising steroidal glycosides from the genus Hoodia, said steroidal glycoside having appetite suppressant activity.
  • the solvents specifically mentioned to perform the extraction are one or more of methylene chloride (dichloromethane), water, methanol, hexane, ethyl acetate or mixtures thereof.
  • An alternative method to obtain an extract is disclosed by separating plant sap from the plant solid material.
  • "Extract" as used herein includes liquid, solid or spray-dried forms of extracts, sap, which also may be purified, partially purified, concentrated and/or fractionated. Other methods of extracting a steroidal glycoside from plants are also suitable.
  • the steroidal glycoside may be incorporated in the form of otherwise concentrated preparation, e.g. a dried plant or otherwise concentrated plant preparation, which preferably contains the same steroidal glycoside amounts as described above with respect to the extract.
  • Steroidal glycoside concentrations may be determined using high performance liquid chromatography (HPLC) with UV detection after extraction or dissolution.
  • Steroidal glycosides may be measured by LC-UV at 220 nm. To this end 20 ⁇ l of the extracts may be injected onto a Zorbax RX-C8 analytical column of 250 x 4.6 mm packed with 5 ⁇ m particles and equipped with a Zorbax RX-C8 guard column of 12.5 x 4.6 mm packed with the same stationary phase. The column system is held at 40°C. Gradient elution is performed starting at 41.2% acetonitrile/methanol (85/15 v/v) and 58.8% water/methanol (85/15 v/v) at a flow rate of 1 ml/min.
  • Compound of Formula 2 (as hereinabove) of any known purity (95% was used in this case) may be used for calibration.
  • Compound 2 may be isolated from an extract of dried Hoodia gordonii using preparative liquid chromatography or may be synthesized (see e.g. US Patent 6,376,657 ).
  • a stock solution at 100 ⁇ g/ml may be prepared in acetonitrile/water (1/1 v/v) and further dilutions are prepared to yield additional calibration standards at 75, 50, 20, 10 and 5 ⁇ g/mL UV response at 220 nm may be used for quantification against the Compound 2 calibration line.
  • Relative response factors based on molecular weight are used to quantify the steroidal glycosides against the Compound 2 calibration line.
  • Steroidal glycosides are defined as all peaks eluting after 15 min that are not present in the blank acetonitrile/water (1/1 v/v) sample.
  • Table 1 Relative retention times and response factors of some steroidal glycosides
  • Compound Relative retention time vs.
  • Compound 2 Response factor vs.
  • Compound 2 formula 2 1.000 1.000 formula 8 1.066 1.164 formula 3 1.128 1.164 formula 4 1.191 1.130 formula 5 1.292 1.146 formula 6 1.328 1.146 formula 7 1.399 1.309
  • the product format of the edible appetite suppressant product is a unit serving drink or bar.
  • a bar weight is from 20 to 100 g, preferably from 25 to 75 g, most preferably from 25 to 60 g.
  • a drink has a volume of 80 to 600 ml, preferably 90 to 400 ml, most preferably from 100 to 350 ml.
  • each unit serving is separately packaged and includes instructions, in particular recommendation of the number of the particular unit serving to be consumed per day.
  • the product of the invention has the energy content of from 200 to 2000 kiloJouLes("kJ"), preferably from 250 to 1900 kJ, more preferably from 300 to 1800 kJ, most preferably from 350 to 1500 kJ, optimally from 400 to 1200 kJ, in order to deliver optimum weight control and nutritional benefits.
  • the energy in the inventive product is delivered through healthy balance of proteins, fats and carbohydrates, as described below.
  • the appetite suppressing unit serving products are formulated to include steroidal glycosides in a defined ratio to the total energy content, such as to achieve the reduction in daily energy intake, yet provide sufficient nourishment, even when product is overused.
  • the ratio of steroidal glycoside amount to total energy content is in the range of from 1:0.5 to 1:10 (mg/kJ), preferably from 1:0.7 to 1:8, most preferably from 1:0.9 to 1:6, optimally from 1:1 to 1:5.
  • inventive compositions include essential minerals selected from the group consisting of phosphorus, iron, zinc, copper, selenium, magnesium, manganese, molybdenum and chromium, especially iron, phosphorous and zinc, and most especially iron as these are considered essential for the nutrition and the lack of one or more of these, and especially iron, in sufficient amounts may Lead to health problems.
  • the minerals described in this paragraph may be added minerals rather than the trace amounts that may be present in various raw ingredients.
  • the preferred ingredients to deliver these minerals include but are not limited to magnesium oxide, ferrous sulfate, ferrous lactate, ferrous fumarate, ferric pyrophosphate, ferric orthophosphate, carbonyl iron, electrolytic iron, NaFeEDTA, ferric orthophosphate, zinc oxide, zinc gluconate, chromium chloride, sodium selenate, manganese sulfate and mixtures thereof.
  • the various minerals may be included in the inventive products in the amounts as follows: Units Range (per unit serving) Preferred range(per unit serving) Mineral Low High Low High Phosphorous mg 100 1000 300 500 Iron mg 1 10 3 7 Zinc mg 1 7 2 6 Magnesium ⁇ g 20 200 80 150 Selenium ⁇ g 3 40 7 25 Chromium ⁇ g 5 50 10 42 Molybdenum ⁇ g 3 40 7.5 27 Manganese mg 0.05 6 0.2 1 Copper mg 0.1 2 0.2 0.6
  • the range of steroidal glycosides to iron is from 25:1 to 500:1 (mg steroidal glycosides: mg iron), preferably from 40:1 to 400:1, most preferably 50:1 to 300:1.
  • the energy content in the inventive products is delivered through a healthy balance of proteins, fats, and carbohydrates.
  • Suitable proteins include but are not limited to milk, skimmed milk, fat free milk, condensed milk, fermented milk, cream, whey, yoghurt, cheese, egg, buttermilk, milk powder, buttermilk powder, cream powder, whey powder, yoghurt powder, cheese powder, egg powder, calcium and sodium caseinates, lactose free dairy proteins, soy proteins, isolated soy proteins, vegetable proteins, meat and fish derived proteins, gelatin, albumin powder, and mixtures thereof.
  • an optimum balance between the amount of proteins and steroidal glycoside amount is maintained, in the range of from 0.5:1 to 200:1 (mg protein: mg steroidal glycoside), preferably from 2:1 to 100:1, most preferably from 5:1 to 75:1.
  • Suitable carbohydrates include but are not limited to potato, pasta, wheat, corn, soy fiber, fruit fiber (e.g. apple and orange),sucrose, fructose, dextrose, lactose, maltodextrins, honey, corn syrup, oligofructose, starches (e.g potato starch, corn starch, rice starch), modified starches, fruit juice, concentrated fruit juice, flours (e.g wheat, corn and rice), gums (e.g.
  • xanthan gum guar gum, gum arabic, locust bean gum, celluloses (e.g sodium carboxy methyl cellulose, microcrystalline cellulose, powdered cellulose), carageenan, potassium carageenan, alginates (e.g sodium and potassium alginates), gelatin, pectin and mixtures thereof.
  • celluloses e.g sodium carboxy methyl cellulose, microcrystalline cellulose, powdered cellulose
  • carageenan e.g sodium and potassium alginates
  • alginates e.g sodium and potassium alginates
  • gelatin pectin and mixtures thereof.
  • sugar may be replaced by artificial sweeteners, or artificial sweeteners may be present in addition to sugars.
  • Artificial sweeteners include but are not limited to aspartame, cyclamates (e.g. Sodium cyclamate), acesulfame K, sucralose, saccharin, invert sugar, maltose sugar, sugar alcohols (e.g maltitol, sorbitol)and mixtures thereof.
  • Suitable fats include but are not limited to saturated and unsaturated fats and oils, for instance sunflower oil, high oleic sunflower oil, canola, cottonseed oil, corn/maize oil, rapeseed oil, olive oil, soybean oil, palm oil, palm kernel oil, coconut, fish oil, linseed oil, peanut/groundnut oil, safflower oil, sesame oil, butter, lard, cocoa butter, mono and diglycerides and mixtures thereof.
  • saturated and unsaturated fats and oils for instance sunflower oil, high oleic sunflower oil, canola, cottonseed oil, corn/maize oil, rapeseed oil, olive oil, soybean oil, palm oil, palm kernel oil, coconut, fish oil, linseed oil, peanut/groundnut oil, safflower oil, sesame oil, butter, lard, cocoa butter, mono and diglycerides and mixtures thereof.
  • the sources of oils and fats can also be hardened (e.g. by hydrogenation) or fractionated (e.g. via solvents) and these can be mixed with other oils or fats.
  • the fat generally from 10 to 80%, preferably from 30 to 50%, by weight of the total fat, may be present as unsaturated or polyunsaturated oil, in particular oils which contain linoleic (e.g sunflower, soybean, corn, Linola tm or rapeseed)or linolenic acid (e.g linseed) and mixtures thereof.
  • oils which contain linoleic e.g sunflower, soybean, corn, Linola tm or rapeseed
  • linolenic acid e.g linseed
  • the product should deliver at least 1g per day of linoleic and/or linolenic acid, preferably from an unsaturated fat source.
  • the inventive products may be, substantially free of trans fat, i.e. contain less then 0.5% of trans fat, preferably less then 0.1%, most preferably less than 0.05% and optimally 0% trans fat, by weight of the product.
  • the general and preferred ranges for the relative amounts of energy from fat and protein in embodiments of the inventive product is as follows: Ranges % energy from fat % energy from protein General 0.5-55 3-50 Preferred 2-45 5-45 Most Preferred 5-40 10-40 Optimal 10-30 10-35
  • carbohydrates deliver the balance of the energy requirement. Generally, this means according to the present invention, that carbohydrates may contribute between 10 and 75% energy in the product. At the preferred, most preferred and optimal ranges, the best nutritional benefit may be delivered at an optimum cost.
  • the especially preferred unit serving drink according to the invention has the following composition, in addition to the steroidal glycoside:
  • the especially preferred unit serving bar according to the invention has the following composition, in addition to the steroidal glycoside:
  • the inventive product is used for suppressing appetite in humans and/or as a product for use in a method of controlling obesity in a human, while at the same time providing at least a minimum nutrition and a balanced intake of essential minerals, proteins, fats, and carbohydrates.
  • At least one inventive product should be ingested per day, typically from 1 to 5 per day (per 24 hours), until reaching the desired weight, and then continuing with this regime to maintain the desired weight. Most preferably, from 1 to 3 products are consumed per day for optimum effect. Most preferably, the inventive products are consumed for at least 14 consecutive days.
  • the inventive products are consumed in addition to the regular energy intake, with a total daily amount of steroidal glycosides from the unit serving products in the range of from 50 mg to 4000 mg, preferably from 70 mg to 2000 mg, most preferably from 90 mg to 1500 mg.
  • the total daily energy intake from the unit serving products is in the range of from 200 kJ to 5000 kJ, preferably from 400kJ to 2000 kJ, most preferably from 600 kJ to 1500 kJ.
  • weight loss of 0.1 kg to 3 kg, preferably from 0.2 kg to 2 kg, most preferably from 0.5 kg to 1 kg per week may be achieved.
  • the particular virtue of the invention is that even at the overuse of the product, sufficient energy levels are provided, to ensure an adequate energy intake for healthy dieting. Furthermore, the right balance between the amount of steroidal glycoside extract and the energy content of the unit serving can be attained.
  • the inventive products are designed to give good nutrition while providing effective reduction in energy to enable steady weight loss. The ratios of steroidal glycoside to total energy, to the essential minerals (especially iron) and to proteins are crucial when balancing the opposing aims of providing weight loss and also the required proper nutrition.
  • the inventive composition preferably includes additional nutrients, vitamins and additional minerals to deliver healthy nutrition, despite the appetite suppression.
  • Suitable vitamins and minerals include but are not limited to Vitamin A, Vitamin D, Vitamin E, Vitamin C, Thiamin, Riboflavin, Niacin, Vitamin B6, folate, Vitamin B12, Biotin, Pantothenic acid, Calcium, Potassium, Sodium, iodine, vitamin K, and mixtures thereof.
  • the preferred ingredients to deliver vitamins and minerals include but are not limited to potassium phosphate, calcium phosphate, magnesium oxide, magnesium phosphate ascorbic acid, sodium ascorbate, vitamin E acetate, niacinamide, ferric orthophosphate, calcium pantothenate, zinc oxide, zinc gluconate, vitamin A palmitate, pyridoxine hydrochloride, riboflavin, thiamin mononitrate, biotin, folic acid, chromium chloride, potassium iodide, sodium molybdate, sodium selenate, phytonadone (vitamin K), cholecalciferol (vitamin D3), cyanocobalamin (vitamin b12), manganese sulfate and mixtures thereof.
  • the inventive product contains at least 10% or more of the recommended daily amount ("RDA") of the vitamins and minerals.
  • Fiber Another especially preferred optional ingredient is fiber.
  • Suitable fiber sources include but are not limited to: inulin /oligofructose, gum arabic, cellulose, cellulose gum, wheat fiber (nutriose), fruit pulp/fiber, pectin, guar gum. Fiber is included generally in an amount of from 0.5-10 g per product, preferably 0.8 to 8, most preferably from 1 to 5.
  • the inventive products may further include meat, fish, meat and fish extracts, fruit, dried fruit, fruit concentrates, fruit extracts, fruit juices, tea (e.g. green tea) vegetables, vegetable extracts and concentrates, nuts, nut extracts, chocolate, bread, vinegar, salt, pepper, cocoa powder, herbs (e.g. parsley), herb extracts, spices (e.g.
  • cinnamon cinnamon
  • spice extracts emulsifiers
  • acidity regulators e.g. phosphoric, malic, citric,tartaric acids and salts thereof
  • flavonoids e.g. phosphoric, malic, citric,tartaric acids and salts thereof
  • preservatives e.g. lactic acid, EDTA, tocopherols, sodium benzoate
  • colors e.g. beta carotene, lycopene, caramel, carmine red
  • fibers e.g. soy
  • leavening agents e.g., sodium bicarbonate
  • pectin citric acid, yeast, salt, glycerine, and mixtures thereof.
  • the preferred inventive products are substantially free of cholesterol, i.e. the products comprise less than 10 mg of cholesterol, preferably no more than 5 mg per unit serving, and optimally are free of cholesterol.
  • the preferred products include sterols and/or stanols for cholesterol lowering effects.
  • the preferred inventive products comprise less than 6g of sodium, preferably less than 3g, most preferably less than 1 g, optimally less than 150 mg per unit serving.
  • the preferred inventive products contain at least 70 mg of potassium, preferably at least 100 mg, most preferably at least 140 mg per unit serving.
  • a steroidal glycoside may be incorporated into the inventive unit serving product in the same manner as any food ingredient.
  • the steroidal glycoside is finely dispersed, preferably delivered in the extract from plants.
  • the extract is prepared as described above, or by CO 2 extraction, or by any other suitable method.
  • appetite suppressant Muesli Bar, Yoghurt Muesli Variant is within the scope of the invention:
  • Nutritional Info Ingredient % Formula Product weight as consumed: 60g Maltitol 4.350 Energy density (kJ/g) 14.62 Glucose syrup 8.403 Energy Per 100g Per 60g Bar Polydextrose syrup 13.344 Inulin syrup 5.600 Energy Value (kJ) 1465 877 Coconut oil 1.000 Energy Value (kcal) 347 208 Mazola oil 2.300 % Energy from Protein - 27.50 Brown Sugar 1.000 % Energy from Carbohydrates - 48.65 Lecithin 0.600 % Energy from Fat - 28.13 Pectose paste 5.000 Trans Fat (g) 0.087 0.052 Glycerine 5.000 % Energy from Trans Fat - 0.23 Date paste 3.000 Linoleic Acid (g) - 1.42 Flavourings 0.405 Sodium (mg) 390 230 Colouring 0.144 Cholesterol (mg) N/A
  • Nutritional Info Ingredient % Formula Product weight as consumed: 295ml Water To 100% Energy density (kJ/g) 2.94 Skimmed Milk Powder 1.218 Energy Per 100ml Per 295ml Sodium Phosphate 0.126 Corn Oil 1.034 Energy Value (kJ) 311 918 Butter Concentrate 0.528 Energy Value (kcal) 74 218 Wheat Flour 2.002 % Energy from Protein - 36.70 Modified Maize Starch 1.575 % Energy from Carbohydrates - 34.68 Flavourings 0.567 % Energy from Fat - 30.14 White Pepper 0.014 Trans Fat (g) N/A N/A Mace Powder 0.007 % Energy from Trans Fat - N/A Maltodextrin 2.800 Linoleic Acid (g) - 1.69 Titanium Dioxide 0.182 Sodium (mg) 360 1060 Garlic Powder 0.028 Cholesterol (mg) N/A N
  • Nutritional Info Ingredient % Formula Product weight as consumed: 325ml Skim Milk 75.300 Energy density (kJ/g) 2.65 Water To 100% Energy Per 100ml Per 325ml Sucrose 6.600 Gum Arabic 1.500 Energy Value (kJ) 281 914 Milk Protein 1.600 Energy Value (kcal) 66 216 Corn Oil 0.600 % Energy from Protein - 25.37 Flavouring 0.200 % Energy from Carbohydrates - 63.89 Emulsifier 0.150 % Energy from Fat - 10.83 Colouring 0.085 Trans Fat (g) 0.006 0.02 Vitamin & Mineral Premix 0.182 % Energy from Trans Fat - 0.08 Plant Extract (80% steroidal glycosides) 0.250 Linoleic Acid (g) 0.32 1.03 Sodium (mg) 60 200 TOTAL 100.00 Cholesterol (mg) N/A N/A Vitamins Per 100ml Per 325ml Vitamin A ( ⁇ g) 86.00 279.
  • the 80% steroidal glycoside had the following specification: Specification item Specification Limit Test method Physical description Form Free flowing powder, free from particulate contamination In-house Colour Light Yellow-green In-house Active Components Steroidal glycosides > 80% HPLC Water content Residual solvents ⁇ 3% Karl Fischer Heptane ⁇ 0.5% Ethanol ⁇ 0.5 % Particle size Microbiological examination ⁇ 50 microns In-house Ph. Eur.
  • the 30% extract had the following specification: Specification item Specification limit Test method Physical description Form Powder, free from particulate contamination In-house Colour Yellow-green In-house Active Components Steroidal glycosides > 30% HPLC Water content ⁇ 5% Karl Fischer Residual solvents Heptane ⁇ 1% Ethanol ⁇ 1 % Particle size ⁇ 100 microns In-house Microbiological examination Ph. Eur. Total viable aerobic count Aerobic bacteria ⁇ 10 4 cfu/g Fungi ⁇ 10 2 cfu/g Enterobacteriaceae ⁇ 10 2 cfu/g Escherichia coli Absent in 1 g Staphylococcus aureus Absent in 1 g Salmonella spp Absent in 10 g
  • a 4000 ml beaker was filled with 1000 ml of the aqueous Hoodia gordonii dispersion containing 8 g Sodium stearoyl lactylate and 8 g Hoodia gordonii extract and 2200 ml demineralised water.
  • the dispersion was reheated to 75 °C under moderate stirring.
  • the vegetable oil was gently added and mixture was stirred for 2-3 minutes.
  • the skim milk powder, the pectin and the sugars/ sweeteners as a powder blend were added and mixed for 5-8 minutes until all lumps had disappeared.
  • the citric acid solution was slowly added to set the pH of the drink to 4.0.
  • demineralised water was added to set the total amount to 4000 g.
  • mice Male Sprague-Dawley rats weighing 210 - 250 g were obtained from Harlan Italy s.r.l. (San.Pietro al Natisone (UD), Italy) and individually housed upon arrival. The animals were maintained under a 12:12 light dark cycle (lights off at 18:00) in a temperature and humidity controlled environment (22 ⁇ 2°C/ 55 ⁇ 15% humidity). The animals were fed a standard rat chow and had free access to tap water.
  • mice were randomly assigned to groups of 10 - 15 animals. Each group received by oral gavage either vehicle (0.5% carboxy methyl cellulose (CMC) in water) or Hoodia gordonii extract (30% steroidal glycosides at a dosage of 10, 30 or 60 mg/kg body weight) suspended in vehicle once per day for a minimum of 14 days. Food intake and body weight were measured daily.
  • CMC carboxy methyl cellulose
  • Hoodia gordonii extract (30% steroidal glycosides at a dosage of 10, 30 or 60 mg/kg body weight
  • Table 2 shows the body weight of rats that received vehicle, 10 mg/kg or Hoodia gordonii extract, 30 mg/kg or Hoodia gordonii extract or 60 mg/kg or Hoodia gordonii extract at day 1 and day 7 of the treatment. Data that were collected are presented as means ⁇ SD. TABLE 2 Body weight (g) Treatment Day 1 Day 7 Vehicle 273 ⁇ 9 307 ⁇ 12 10 mg/ kg Hoodia gordonii extract 272 ⁇ 8 269 ⁇ 15* 30 mg/ kg Hoodia gordonii extract 269 ⁇ 9 241 ⁇ 9* 60 mg/ kg Hoodia gordonii extract 271 ⁇ 9 236 ⁇ 11*
  • Table 3 shows the daily food intake of rats that received vehicle, 10 mg/kg or Hoodia gordonii extract, 30 mg/kg of Hoodia gordonii extract or 60 mg/kg of Hoodia gordonii extract at day 7. Data are presented as means ⁇ SD. TABLE 3 Treatment Daily Food Intake at Day 7 (g/ animal/ day) Decrease in Food Intake at Day 7 (% of control) Vehicle 26.7 ⁇ 2.1 0 10 mg/ kg Hoodia gordonii extract/ day 15.9 ⁇ 5.2 40 ⁇ 19 30 mg/ kg Hoodia gordonii extract/ day 7.6 ⁇ 2.5 72 ⁇ 9 60 mg/ kg Hoodia gordonii extract/ day 5.9 ⁇ 1.4 78 ⁇ 5
  • Example 6 The data from Example 6 are used to show the effects of simultaneous consumption of a nourishing amount of energy and steroidal glycoside on energy intake in humans, assuming a person of 70 kg with an average daily energy consumption of 10,000 kJ and assuming 20% reduction in energy intake from 350 mg steroidal glycosides, 40% reduction in energy intake from 700 mg steroidal glycosides, 60% reduction in energy intake from 1050 mg steroidal glycosides, 72% reduction in energy intake from 2100 mg steroidal glycosides and 78% reduction in energy intake from 4200 mg steroidal glycosides.
  • Table 4 shows the decrease in energy intake in such a typical person after consuming increasing numbers of unit servings.
  • Product A (outside the scope of the invention) contains a very low amount of energy, i.e.
  • the amount of steroidal glycoside in the unit serving is balanced with a nourishing amount of energy (i.e. 800 kJ) This energy adds to the total daily energy intake of the person consuming the unit servings, resulting in a 12% to 36% reduction of energy intake over a wide range of unit servings consumed per day.
  • Product B (outside the scope of the invention) contains too high amount energy per unit serving, with the result that the reduction in energy intake caused by steroidal glycoside is reversed by the energy of the unit servings as shown and no reduction in daily energy intake is observed. As shown, the right balance between the amount of the steroidal glycoside and the amount of energy in the unit serving determines the maximum decrease in energy intake.
  • the reduction in energy intake is 1200 to 3600 kJ over a wide range of unit servings consumed per day.
  • TABLE 4 Total Daily Energy Intake (kJ/ day) Number Unit Serving s per Day
  • Product 1 350 mg steroidal glycoside and 800 kJ energy (1:2.3 ratio)
  • Product 2 350 mg steroidal glycoside and 2000 kJ energy (1:5.7ratio)
  • Product A 350 mg steroidal glycoside and 100 kJ energy (3.5:1 ratio)
  • Product B 350 mg steroidal glycoside and 2600 kJ energy (1:7.4 ratio) 1 8,800 10,000 8,100 10,600 2 7,600 10,000 6,200 11,200 3 6,400 10,000 4,300 11,800 6 7,600 14,800 3,400 14,800 12 11,800 26,200 3,400 33,400

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (32)

  1. Produit anorexigène comestible en dose unitaire, sous la forme d'une barre ayant un poids de 20 g à 100 g ou d'une boisson ayant un volume de 80 ml à 600 ml, le produit comprenant :
    (a) de 50 à 2000 milligrammes d'un glycoside stéroïdien pouvant être obtenu à partir de plantes du genre Hoodia ;
    (b) de 200 à 2000 kilojoules d'énergie totale ;
    (c) le rapport glycoside stéroïdien sur énergie totale de 1/05 à 1/10 mg/kJ ;
    (d) un minéral essentiel choisi dans le groupe constitué du phosphore, du fer, du zinc, du cuivre, du sélénium, du magnésium, du manganèse, du molybdène, du chrome et de leurs mélanges.
  2. Produit selon la revendication 1, comprenant de 70 mg à 1500 mg du glycoside stéroïdien.
  3. Produit selon l'une quelconque des revendications précédentes, comprenant de 90 mg à 1100 mg du glycoside stéroïdien.
  4. Produit selon l'une quelconque des revendications précédentes, dans lequel le glycoside stéroïdien peut être obtenu à partir de plantes choisies dans le groupe constitué de Trichocaulon piliferum, Trichocaulon officinale, Hoodia currorii, Hoodia gordonii, Hoodia lugardii et leurs mélanges.
  5. Produit selon l'une quelconque des revendications précédentes, dans lequel le glycoside stéroïdien peut être obtenu à partir de Hoodia gordonii.
  6. Produit selon l'une quelconque des revendications précédentes, dans lequel le glycoside stéroïdien est incorporé dans le produit sous la forme d'une préparation concentrée pouvant être obtenue à partir de plantes.
  7. Produit selon la revendication 6, dans lequel la préparation concentrée comprend au moins 10 % du glycoside stéroïdien, en poids de la préparation concentrée.
  8. Produit selon l'une quelconque des revendications précédentes, dans lequel le glycoside stéroïdien est incorporé dans le produit sous la forme d'un extrait pouvant être obtenu à partir de plantes.
  9. Produit selon l'une quelconque des revendications précédentes, dans lequel le glycoside stéroïdien comprend un désoxy- ou di-désoxy-glycoside.
  10. Produit selon l'une quelconque des revendications précédentes, dans lequel le glycoside stéroïdien possède la formule générale (1) :
    Figure imgb0013
     dans laquelle
    R = alkyle ;
    R1 est choisi dans le groupe constitué de H, d'un alkyle, d'un tiglyol, d'un benzoyle et d'un groupe ester organique ;
    R2 est choisi dans le groupe constitué de H, ou d'un ou de plusieurs 6-désoxy-glucides, ou d'un ou de plusieurs 2,6-didésoxy-glucides, d'un radical glucose et de leurs mélanges ; et dans laquelle les lignes pointillées indiquent la présence optionnelle d'une liaison supplémentaire entre les atomes de carbone C4 et C5 ou entre les atomes de carbone C5 et C6.
  11. Produit selon l'une quelconque des revendications précédentes, dans lequel les minéraux essentiels sont choisis dans le groupe constitué du fer, du phosphore et du zinc.
  12. Produit selon l'une quelconque des revendications précédentes, dans lequel le glycoside stéroïdien comprend un composé de formule (2) :
    Figure imgb0014
  13. Produit selon l'une quelconque des revendications précédentes, dans lequel le minéral essentiel est le fer.
  14. Produit selon la revendication 13, dans lequel le rapport glycoside stéroïdien sur fer est situé dans la plage allant de 25/1 à 500/1 (mg/mg).
  15. Produit selon l'une quelconque des revendications précédentes, dans lequel le produit contient 250 kJ à 2000 kJ d'énergie totale.
  16. Produit selon l'une quelconque des revendications précédentes, dans lequel le rapport glycoside stéroïdien sur la quantité totale d'énergie est situé dans la plage allant de 1/0,7 mg/kJ à 1/8 mg/kJ.
  17. Produit selon l'une quelconque des revendications précédentes, dans lequel de 3 % à 50 % de l'énergie totale proviennent des protéines.
  18. Produit selon l'une quelconque des revendications précédentes, sous la forme de la boisson en dose unitaire comprenant en plus du glycoside stéroïdien :
    de 75 % à 95 % en poids d'humidité ;
    de 0,5 % à 10 % en poids de protéines ;
    de 0,5 % à 6 % en poids de matières grasses ;
    de 3 % à 20 % en poids de glucides ;
    et jusqu'à 8 % en poids d'ingrédients optionnels.
  19. Produit selon l'une quelconque des revendications précédentes, sous la forme de la barre en dose unitaire comprenant en plus du glycoside stéroïdien :
    de 3 % à 30 % en poids d'humidité ;
    de 3 % à 30 % en poids de protéines ;
    de 3 % à 30 % en poids de matières grasses ;
    de 35 % à 80 % en poids de glucides ;
    et jusqu'à 12 % en poids d'ingrédients optionnels.
  20. Produit selon l'une quelconque des revendications précédentes, dans lequel le rapport pondéral protéines sur glycoside stéroïdien est situé dans la plage allant de 0,5/1 à 200/1.
  21. Procédé non thérapeutique de suppression de l'appétit chez un humain tout en fournissant également une alimentation suffisante, le procédé comprenant l'ingestion par l'humain du produit selon la revendication 1.
  22. Procédé selon la revendication 21, le procédé comprenant l'ingestion du produit 1 à 5 fois par jour.
  23. Procédé selon la revendication 21, le procédé comprenant l'ingestion du produit 1 à 3 fois par jour.
  24. Procédé selon la revendication 21, permettant d'atteindre une réduction de prise énergétique quotidienne chez un adulte humain de 750 kJ à 4500 kJ par jour.
  25. Procédé selon la revendication 21, dans lequel le produit est consommé pendant au moins 14 jours.
  26. Procédé selon la revendication 21, dans lequel la prise énergétique quotidienne totale fournie par les produits en dose unitaire est de 200 kJ à 5000 kJ.
  27. Produit selon la revendication 1, pour son utilisation dans un procédé de lutte contre l'obésité chez un humain tout en fournissant également une alimentation suffisante, dans lequel l'humain ingère le produit.
  28. Produit pour son utilisation selon la revendication 27, le procédé comprenant l'ingestion du produit 1 à 5 fois par jour.
  29. Produit pour son utilisation selon la revendication 27, le procédé comprenant l'ingestion du produit 1 à 3 fois par jour.
  30. Produit pour son utilisation selon la revendication 27, moyennent quoi le procédé permet d'atteindre une réduction de prise énergétique quotidienne chez un adulte humain de 750 kJ à 4500 kJ par jour.
  31. Produit pour son utilisation selon la revendication 27, dans lequel le produit est consommé pendant au moins 14 jours.
  32. Produit pour son utilisation selon la revendication 27, dans lequel la prise énergétique quotidienne totale fournie par les produits en dose unitaire est de 200 kJ à 5000 kJ.
EP07730088.7A 2006-06-13 2007-06-12 Compositions comestibles supprimant l'appetit contenant des glycosides steroïdiques Not-in-force EP2026666B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07730088.7A EP2026666B1 (fr) 2006-06-13 2007-06-12 Compositions comestibles supprimant l'appetit contenant des glycosides steroïdiques

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06115404 2006-06-13
PCT/EP2007/055764 WO2007144347A2 (fr) 2006-06-13 2007-06-12 Unité servant des compositions anorexigènes avec des glycosides stéroïdiens
EP07730088.7A EP2026666B1 (fr) 2006-06-13 2007-06-12 Compositions comestibles supprimant l'appetit contenant des glycosides steroïdiques

Publications (2)

Publication Number Publication Date
EP2026666A2 EP2026666A2 (fr) 2009-02-25
EP2026666B1 true EP2026666B1 (fr) 2015-06-10

Family

ID=38667150

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07730088.7A Not-in-force EP2026666B1 (fr) 2006-06-13 2007-06-12 Compositions comestibles supprimant l'appetit contenant des glycosides steroïdiques

Country Status (10)

Country Link
EP (1) EP2026666B1 (fr)
JP (1) JP2009539930A (fr)
CN (1) CN101466275A (fr)
AU (1) AU2007260087B2 (fr)
BR (1) BRPI0711240A2 (fr)
CA (1) CA2654286A1 (fr)
CL (1) CL2007001716A1 (fr)
MX (1) MX2008015252A (fr)
RU (1) RU2009100892A (fr)
WO (1) WO2007144347A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041902A1 (en) * 2007-08-10 2009-02-12 Jadwiga Malgorzata Bialek Composite food product in a pack comprising fibers and method for preparing such product
US7923435B2 (en) 2008-04-21 2011-04-12 Phytopharm Plc Hoodia plant extract with improved flavor
JP2014079208A (ja) * 2012-10-17 2014-05-08 Ryozo Saito 腸内環境及び腸管バリア改善サプリメント
BR112019005785A2 (pt) * 2016-09-29 2019-06-18 Nestec Sa métodos que reduzem os desejos alimentares, pro-movem perda de peso e/ou tratam sobrepeso ou obesidade

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966918A (en) * 1973-12-12 1976-06-29 Nippon Shinyaku Co., Ltd. Method of preparing aqueous solutions of sterol glycosides and their ester derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE9900497A (et) * 1997-04-15 2000-06-15 Csir Söögiisu pärssiva toimega farmatseutilised kompositsioonid
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
EP1994837A3 (fr) * 2001-11-16 2009-11-11 Nestec S.A. Matériau pouvant être dérivé ou à base de plantes avec une activité coupe-faim
GB0320990D0 (en) * 2003-09-08 2003-10-08 Unilever Plc Food composition
US20050276839A1 (en) * 2004-06-10 2005-12-15 Rifkin Calman H Appetite satiation and hydration beverage
US20060083795A1 (en) * 2004-10-19 2006-04-20 Lima Shatkina Meal replacement products having appetite suppressing qualities

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966918A (en) * 1973-12-12 1976-06-29 Nippon Shinyaku Co., Ltd. Method of preparing aqueous solutions of sterol glycosides and their ester derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHONER W: "Endogenous cardiac glycosides, a new class of steroid hormones", EUROPEAN JOURNAL OF BIOCHEMISTRY, BLACKWELL PUBLISHING, BERLIN, DE, vol. 269, 1 January 2002 (2002-01-01), pages 2440 - 2448, XP002367830, ISSN: 0014-2956, DOI: 10.1046/J.1432-1033.2002.02911.X *

Also Published As

Publication number Publication date
RU2009100892A (ru) 2010-07-20
AU2007260087A1 (en) 2007-12-21
BRPI0711240A2 (pt) 2011-08-30
CN101466275A (zh) 2009-06-24
EP2026666A2 (fr) 2009-02-25
MX2008015252A (es) 2008-12-17
JP2009539930A (ja) 2009-11-19
WO2007144347A3 (fr) 2008-05-22
CA2654286A1 (fr) 2007-12-21
AU2007260087B2 (en) 2011-02-10
CL2007001716A1 (es) 2008-01-25
WO2007144347A2 (fr) 2007-12-21

Similar Documents

Publication Publication Date Title
US20080003268A1 (en) Unit serving appetite suppressant compositions with steroidal glycosides
EP1662903B1 (fr) Composition alimentaire
US9393190B2 (en) Methods for enhancing skin tan and reducing risks of UV skin damage
JP4866914B2 (ja) 心血管系疾患の予防においてプラス効果を有する機能性食品
CN111528483A (zh) 一种均衡营养的功能代餐粉及其制备方法
WO2012097064A1 (fr) Compositions nutritionnelles et procédés pour contrôler le glucose dans le sang
US20090042813A1 (en) Hoodia extract oil compositions comprising medium chain triglycerides
WO2012097061A1 (fr) Compositions nutritionnelles et procédés pour améliorer le métabolisme protéique des muscles squelettiques
EP3541206B1 (fr) Composition nutritionnelle à utiliser dans la thérapie de patients atteints de fragilité et/ou de sarcopénie ou de pré-sarcopénie ou de fragilité précoce
CN106061291A (zh) 使用绿茶提取物来增加骨骼肌蛋白质合成的方法
KR20100044204A (ko) 식품 조성물
EP2026666B1 (fr) Compositions comestibles supprimant l'appetit contenant des glycosides steroïdiques
CN101248876B (zh) 一种降胆固醇保健饮料
RU2525338C2 (ru) Инстантный функциональный пищевой продукт
JP2008044872A (ja) イソラリシレシノールを含有する健康食品、血中コレステロール降下剤および体脂肪低下剤
JP6964290B2 (ja) Ａｔｐ産生促進用剤
US20110212191A1 (en) Composition for the maintenance of blood sugar levels comprising cinnamon and ginseng
Balasubramanian et al. Peanut as a smart food and their nutrients aspects in planet: a review
US20060210659A1 (en) Anti-obesity agent
US20120288573A1 (en) Use of extracts from salonum glaucophyllum for treating bone metabolism disorders and kidney disorders
US20120301573A1 (en) Composition and method for suppressing appetite
WO2014176222A1 (fr) Supplément nutritionnel pour la gestion du poids
Dini Kancolla Seeds: High Nutritional Foods With Nutraceutical Properties
KR101477765B1 (ko) 비만의 예방 및 관리에 유용한 식이조성물
KR20190035290A (ko) 콩발아배아 추출물을 포함하는 숙취의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20091027

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

INTG Intention to grant announced

Effective date: 20140827

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141001

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CSIR

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 730524

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007041742

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 730524

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150610

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150911

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150910

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602007041742

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A23L0001290000

Ipc: A23L0033000000

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151010

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150610

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007041742

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150612

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150630

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150630

26N No opposition filed

Effective date: 20160311

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20070612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150612

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150610

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180530

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20180529

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180606

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007041742

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190612

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190630